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ABSTRACT 
DNA minor groove binding compounds have had limited therapeutic uses, in part due to 
problems with sequence specificity. A two-site model has been developed to enhance 
specificity, in which compounds bind to two short AT sites separated by one or two GC 
base pairs. Using thermal melting, heterocyclic dications with this capability were tested 
with various oligonucleotides for binding affinity and specificity. Compounds of interest 
were further probed using circular dichroism, mass spectrometry, biosensor-SPR, and 
molecular modeling. Several compounds were found to “jump” a GC base pair, binding 
to AT sites in the minor groove of DNA with a two-site recognition mode. One 
compound was also found to recognize a single intervening GC base pair. Compounds 
with terminal, non-polar amidine extensions were found to have increased DNA binding 
compared to analogs with terminal amidines. This unique, two-site DNA recognition 
mode offers novel design principles to recognize entirely new DNA motifs. 
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1 INTRODUCTION 
 
1.1 Nucleic Acids as Drug Targets 
The human body is based upon the language of molecules, and through their 
interactions states of wellness and disease are created. The effects, and often the root 
causes of disease can be traced back to aberrant transcriptional pathways. The 
biological system of transcription is complex and dynamic, consisting of proteins, 
nucleic acids, co-factors, and other compounds whose interactions maintain life. By 
targeting nucleic acids in a sequence-specific manner with small, cell-permeable 
molecules, cellular regulation and genomic reprogramming may become medicines of 
the future.1  
With the advent of the human genome project, nucleic acids have become an 
increasingly popular target, both for basic research and for novel therapeutics. Current 
and early anti-cancer drugs target DNA, including actinomycin D and cisplatin.2 The 
treatment for tuberculosis, streptomycin, specifically targets ribosomal RNA in the 
pathogenic microorganism.2b Aromatic diamidines such as pentamidine, currently used 
as treatment, target the minor groove of kinetoplast DNA (kDNA) in the trypanosome 
parasite responsible for African sleeping sickness. These circular kDNAs are interlocked 
similarly to chain mail, and are found inside the protozoan’s mitochondria. Since there 
are no equivalent nucleic acid structures in humans, these sites are attractive targets for 
antiparasitic drug development.2b, 3 The kinetoplast sites are rich in AT base pairs, 
where classical heterocyclic dications prefer to bind.3a, 3c, 4 However, human DNA also 
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contains sites rich in AT base pairs; thus greater sequence specificity must be 
developed to increase the therapeutic index of this class.  
 
1.2 Two-site Approach 
The AT sites found in kinetoplast minicircles of mitochondrial DNA are often 
separated by one or more GC base pairs (BPs); a common motif is 3-4 AT BPs 
separated by 1-2 GC BPs.3a If this sequence-specific feature could be selectively 
targeted, minor groove binding agents could be improved as anti-parasitic agents with 
fewer side effects. The minor groove of an AT BP (Figure 1) has two hydrogen bond 
acceptor sites, the N3 of adenine and the C2 carbonyl of thymine; and is easily 
recognizable by heterocyclic groups with hydrogen bond donors.4-5 The minor groove of 
a GC BP has one hydrogen bond donor group, the C2 amine group of guanine, and two 
acceptors, the N3 of guanine and the C2 carbonyl of cytosine. However, the protruding 
exocyclic amine group of guanine presents a steric hindrance to deep minor groove 
binding, and recognition is challenging.  
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Figure 1. Structure of DNA base pairs.4 Adenine-thymine (AT) and guanine-cytosine 
(GC) are illustrated with major and minor grooves indicated. Note the exocyclic amine of 
guanine protruding into the minor groove. 
 
AT-rich sequences, especially poly-dA oligonucleotides, have other unique 
characteristics. The minor grove of such sequences is compressed, resulting in 
increased negative electrostatic potential.4, 6 Introduction of alternating A-T “steps” 
lessens this effect. If intervening GC BPs are introduced, the minor groove widens, and 
the resulting electrostatic potential is relatively decreased in magnitude. Because of 
these minor groove characteristics, preferential binding to GC BPs is both sterically and 
electrostatically challenging. By linking two AT recognizing moieties (Figure 2), 
compounds that “jump” the GC BPs can be designed. A linker capable of recognizing 
the GC BPs is a future goal. 
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Figure 2. Two-site concept. Initially, AT-recognizing compounds bind 3-4 AT base 
pairs each. The two are joined together with a linker, and can span 1-2 intervening GC 
base pairs for a longer cognate binding site. 
 
A two-site approach has been used with a variety of DNA binding systems. 
Pyrrolo[2,1-c][1,4]benzodiazepines (PDBs) such as tomamycin and anthramycin are 
antitumor antibiotic agents currently used clinically.7  These compounds bind to the 
minor groove, covalently bonding to the exocyclic C2-NH2 of a guanine base. Two such 
PDBs have been joined via a diether linkage (i.e. -O-(CH2)n-O-), and various homologs 
tested for linker length optimization. The homolog studies show that three and five 
methylene groups correlate with guanine separation of two and three BPs respectively, 
with the two covalent bonds forming on opposite strands. Similarly, to serve as a probe 
for higher-ordered DNA structures, two Hoechst 33258 moieties have been joined with 
an oligo-ethylene glycol linker.8 Hoechst 33258 is known to strongly bind to the minor 
groove of DNA at an AT rich site (A3T3). The bidentate compounds bind to the minor 
groove of DNA at two AT sites, showing cooperative binding as well as site 
discrimination.  
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Other examples include polyamides, minor groove binders based on the natural 
products netropsin and distamycin A, which can be programmed for binding in a 
sequence specific manner.1a, 9 Hairpin polyamides have been connected together head-
to-head via alkyl linkers (i.e. -CO(CH2)nCO-). The resulting compounds bind one hairpin 
moiety to each of two adjacent binding sites, spanning 10-11 BP.9c  Linker optimization 
studies showed that two methylene groups are preferred for jumping two AT BPs. 
Polyamides have also been developed that bind as overlapped dimers.10 These 
compounds break the cognate sequence into two halves, binding to AT rich opposite 
sides of the binding site and stacking in the mixed BP center. Known as combilexins, 
compounds have also been designed that combine a polyamide-type minor groove 
binder with an intercalating agent, resulting in anticancer molecules that bind with two 
different modes to two different sites.11 
Successful implementation of a two-site model would result in compounds that 
are thermodynamically driven towards complex formation with longer binding sites. 
Binding with a single site would leave half of the ligand unbound, resulting in a high 
energy, unstable complex. Such selectivity promises enhanced recognition, which is 
necessary for genome-regulating compounds as well as for a new generation of anti-
kDNA therapeutics. 
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1.3 Purpose of This Study 
Minor groove DNA binding compounds hold great potential for new drugs, not 
only as anti-parasitics, but also as human genome regulators that can target other 
diseases. For this to become a reality a greater understanding of compound structure 
vs. selectivity must be developed. In order to keep the synthetic price of potential 
therapeutics relatively low, this study focuses on symmetrical molecules. Although 
sequence-specific polyamides can be designed and synthesized, they are currently 
expensive and impractical as new drug candidates. Other minor groove binding 
heterocyclic groups such as benzimidazole and hydroxybenzimidazole have been 
developed that show promising selectivity;1a, 9b however, no true substitution for 
polyamide sequence recognition has yet been discovered. This study screens a number 
of heterocyclic dications (Figure 3) against a variety of DNA sequences (Figure 4). From 
the resulting matrix of data, structure-activity relationships can be derived that further 
this goal. The sequence (AAG)3 is a specific target for binding. This sequence is 
repeated many times in the genetic disease Friedreich’s Ataxia, causing irregular DNA 
hairpin formations. The body’s repair mechanisms are ineffective at removing these 
repeats, resulting in “sticky” DNA that forms a triplex structure.12 Stabilizing the duplex 
form of this DNA by minor groove binding molecules is a novel treatment approach. 
Unlike many minor groove binders, heterocyclic dications are readily cell-permeable; 
increased selectivity will open the door for new drug development.  
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Figure 3. Heterocyclic diamidine and cyanine dye structures. Group I compounds 
consist of conformationally limited, conjugated ring systems with predominantly phenyl-
benzimidazole-amidine terminals; Group II compounds consist of similar systems with a 
more flexible, central region connected via diether linkage; Group III compound consist 
of compounds with a longer, flexible linker region and phenyl-furan-phenyl terminals; 
and Group IV compounds consist of conformationally limited, conjugated ring systems 
with sulfur introduced.  
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Figure 4. DNA seuqences tested. Shorthand is listed to the left of each 
oligonucleotide, and will be used to refer to the sequences throught the text. Hairpin and 
self-complementary DNA sequences were selected with a variety of binding sites and 
similar flanking sequences. A4T4 is the two-site sequence with no intervening GC BPs, 
and A3T3 the shortened version, selected as a test for binding site length. A4 is the 
single-site control. A variety of two-site sequences with one or two intervening GC BPs 
were selected (A4GT4, A4CT4, A4GCT4, and A3CT3), as well as the Friedreich’s Ataxia 
sequence, (AAG)3, which can be thought of as a shortened two-site or three-site 
sequence. The sequence (AT)4 was selected to compare an A-T step sequence to the 
A-tract sequences. 
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2 EXPERIMENTAL 
 
2.1 Buffer and Sample Preparation 
 
2.1.1 Cacodylic Acid Buffer 
Cacodylic acid (CCL), disodium ethylenediamine tetraacetic acid (EDTA), sodium 
hydroxide (1 N), and sodium chloride were obtained from Fisher Scientific (Fairlawn, 
NJ). Nanopure water was obtained using an ELGA Purelab Classic water purification 
system. Cacodylic acid (10 mM), NaCl (100 mM), and EDTA (1 mM) were dissolved into 
nanopure water by stirring over low heat. An Accumet pH Meter 910 (Fisher Scientific) 
was used to monitor pH, and the buffer was titrated using NaOH until the pH reached 
6.2. The solution was transferred into a Kimax volumetric flask and made up to the mark 
with additional nanopure water. 
 
2.1.2 2[N-Morpholino]ethanesulfonic Acid Buffer 
Surfactant P20 was obtained from GE Healthcare (Uppsala, Sweden), 2[N-
morpholino]ethanesulfonic acid (MES) was obtained from Sigma Chemical Company 
(St. Louis, MO), and sodium hydroxide was obtained from Fisher Scientific (Fairlawn, 
NJ). MES (10 mM), NaCl (100 mM) and EDTA (0.1 mM) were dissolved into nanopure 
water by stirring over low heat. The solution was titrated with NaOH to a pH of 6.2, and 
the total volume made up in a volumetric flask as described above. Surfactant P20 
(0.005% or 0.05%, v/v) was added, and the solution filtered and degassed using a 
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vacuum filtration apparatus with 0.22 µm nitrocellulose filter paper (Millipore, Billerica, 
MA). 
 
2.1.3 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic Acid Buffer 
 Hydrochloric acid (1 N) was obtained from Fisher Scientific (Fairlawn, NJ), and 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) was obtained from Sigma 
Chemical Company (St. Louis, MO). HEPES (10 mM), NaCl (100 mM) and EDTA (0.1 
mM) were dissolved into nanopure water by stirring. The solution was titrated with 
hydrochloric acid to a pH of 7.4, and the total volume made up in a Kimax volumetric 
flask. Surfactant P20 (0.05% v/v) was added, and the solution filtered and degassed as 
described above. 
  
2.1.4 Compound Preparation 
All DB compounds were synthesized in Professor David Boykin's laboratory 
(GSU, Atlanta, GA). Cyanine dyes (3,3’-diethylthiadicarbocyanine iodine, 3,3’-
diethylthiacyanine iodide, and 3,3’-diethylthiacarbocyanine iodide) were obtained from 
Aldrich Chemical Company (Milwaukee, WI). Stock solutions of compounds (0.3 - 1 
mM) were prepared in nanopure water with 0-30% DMSO added if necessary for 
dissolution. Extinction coefficients for selected compounds were obtained using a Cary 
300 Bio UV-vis spectrophotometer (Varian) run from 800-200 nm at 60 nm/min. A plot of 
concentration vs. peak absorbance was created using Kaleidagraph software, and the 
slope taken to be the extinction coefficient of the compound as evident from the Beer-
Lambert law. 
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2.1.5 Oligonucleotide Preparation 
Oligonuleotides were obtained from Integrated DNA Technologies (Coralville, IA). 
Solutions were prepared by adding nanopure water to the oligonucleotide vial for ~1 mM 
concentration. These concentrations were checked by using the simple reads function 
of a Cary 300 Bio UV-vis spectrophotometer (Varian) at 260 nm. The absorbance 
values of five titrations of DNA stock solution were averaged and used to determine 
concentration based on the Beer-Lambert Law. 
 
2.2 Thermal Melting 
Binding of compounds to oligonucleotides was screened by thermal melting 
using a Cary 300 Bio UV-vis spectrophotometer (Varian). Samples of DNA and 
compound in buffer (1000 μL) were prepared in 1 cm quartz cuvettes at various ratios 
(e.g. 0:0 (buffer blank), 0:1 (DNA), 1:1, 2:1 and 3:1), and were annealed prior to being 
tested. For bulk screening purposes, different compounds at a 2:1 ratio were tested at 
the same time. A concentration of 3 μM DNA was used unless significant aggregation 
occurred, in which case a concentration of 1 μM DNA was used. The machine was set 
to test a single ramp at 260 nm and 0.5° C/min, beginning well below the native melting 
temperature and ending well above it or at 95.00° C. The absorbance of the buffer was 
subtracted, and a graph of normalized absorbance vs. temperature was created using 
Kaleidagraph software. The ΔTm values were calculated using a combination of the 
derivative function and estimation from the normalized graphs.13 
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2.3 Circular Dichroism 
Circular dichroism studies were performed using a Jasco J-810 instrument. Four 
spectra were averaged from 500 to 220 nm, using a 1 cm quartz cuvette, a scan speed 
of 50 nm/min, and a response time of 1 sec. A cacodylic acid buffer spectrum was taken 
first, followed by DNA in the same buffer (3 μM).  Compound was then titrated into the 
solution, taking a spectrum at each new concentration until saturation was reached. 
Buffer subtracted graphs were created using the Kaleidagraph software. 
 
2.4 Mass Spectrometry 
Hairpin oligonucleotide solutions were desalted three times using 150 mM 
ammonium acetate (Sigma-Aldrich, St. Lious, MO) buffer and a 1000 Da cut-off 
membrane (Spectrum Laboratories Inc., Rancho Dominguez, CA). A concentration of 5 
μM of each oligonucleotide was run together with an appropriate amount of compound 
to yield the desired ratio, reported as [compound]:[each oligonucleotide]. Compounds 
were prepared in ammonium acetate buffer (150 mM) with or without 5% (v/v) methanol 
(Fisher Scientific, Fairlawn, NJ). Electrospray ionization mass spectrometry on a 
negative mode was performed using a Waters Micromass Q-TOF micro (ESI-Q-TOF, 
Milford, MA) instrument. ‘Soft’ ionization conditions were used, with a capillary voltage 
of 2.5 kV, sample cone voltage of 30 V, source block temperature of 70° C, desolvation 
temperature of 100° C, nitrogen as the nebulizing and drying gas, and direct injection at 
5 μL/min. Spectral information was recorded in the mass/charge region 300-3000, and 
MassLynx 4.1 software used for data analysis. 
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2.5 Surface Plasmon Resonance 
Surface plasmon resonance (SPR) was conducted using a four-channel Biacore 
2000 or Bia T200 optical biosensor system (Biacore, GE Helthcare Inc.). Hairpin 
oligonucleotides biotin labeled at the 5’ end were immobilized on to streptavidin-coated 
sensor chips (Biacore SA) as described in the literature.1b, 2b, 14 One flow cell was left 
blank as a reference, and the three remaining cells immobilized with ~350 RU DNA. 
Filtered, degassed MES or HEPES buffer was used for all SPR experiments. Serially 
diluted compound samples were prepared and tested, and the resulting sensorgrams fit 
using steady state models.2b, 14a Data processing was performed using the 
BIAevaluation software (Biacore, GE Heathcare Inc.) and Kaleidagraph software. 
 
2.6 Molecular Modeling 
Compounds were modeled using Spartan ’04 running on a Windows XP platform. 
Molecules were drawn and the molecular geometry minimized with molecular 
mechanics based on the MMFF force field after the addition of each group. Next, an 
equilibrium conformer calculation was performed using the MMFF force field. This 
output was further refined by calculating the equilibrium geometry using a Hartree-Fock 
model with a 6-31G* basis set. A high-resolution electrostatic potential map was 
generated by mapping the electrostatic potential onto an electron density surface.15 
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3 RESULTS 
 
3.1 Extinction Coefficients 
UV-vis absorption spectra were measured to determine if the compounds studied 
resulted in linear Beer-Lambert plots, as well as to determine extinction coefficient 
values. An example of spectral series and extinction coefficient are shown in Figure 5 
for DB321. Despite their hydrophobicity, compounds typically resulted in linear Beer-
Lambert plots throughout the concentration range tested (1-20 µM), with extinction 
coefficients in the range of 4 x 104 - 7 x 104 L/(M*cm), and peak absorbances between 
270 and 400 nm. 
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  Figure 5: Extinction coefficient graphs for DB321. For DB321, a peak absorbance 
value at 381 nm can be found from the plot of absorbance vs. wavelength. As with the 
other compounds, the extinction coefficient was found from the slope of the best-fit line 
of a plot of peak absorbance vs. concentration. 
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Table 1: Extinction coefficients and peak absorbances of selected compounds. 
The extinction coefficient values were calculated using the Beer-Lambert Law, 
measuring the absorbance of various ratios of compound at the wavelength with 
maximum absorbance. 
Compound Extinction Coefficient (L/(M*cm)) Peak Absorbance (nm) 
DB321 5.0 x 104 381 
DB462 6.5 x 104 365 
DB510 5.2 x 104 366 
DB1947 6.8 x 104 277 
DB2148 4.4 x 104 313 
 
 
 
3.2 Thermal Melting 
Thermal melting experiments were performed as a robust screening method for 
relative binding affinity. The method is illustrated in Figure 6, with different compounds 
and different DNA sequences. 
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Figure 6. Selected thermal melting graphs (see Appendix for additional graphs). The 
change in thermal melting temperature was found by melting samples of DNA with 
compound at various ratios, and examining the change in the graph of normalized 
absorbance vs. temperature. Samples were typically prepared with 3 μM DNA, in either 
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CCL or MES buffer at pH 6.2. Typically a ratio of 2:1, [compound]:[DNA], was used to 
compare relative binding affinities. For compounds with abnormal graphs the derivative 
function occasionally failed to produce an accurate Tm value. In these cases, the ΔTm 
value was estimated from the graph.13 
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Figure 7. Comparison of CCL and MES buffers using thermal melting. Samples 
were tested with 3 μM DNA in either CCL or MES buffer at pH 6.2. Compounds were 
assumed to bind as either monomers or dimers, and so a 2:1 ratio was chosen for 
comparison. The ΔTm results for A4CT4 with DB2232, DB2237, and DB2238 were the 
same in CCL and MES buffers, indicating that these buffers can be used equivalently in 
thermal melting experiments.  
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Table 2: ΔTm results of various compounds and oligonucleotides. Compounds 
were tested with 3 μM or 1 μM DNA in either CCL or MES buffer (100 mM NaCl) at pH 
6.2. ΔTm was calculated in degrees centigrade from (Tm with compound) - (Tm without 
compound) at a 2:1 ratio of compound to duplex DNA, and is assumed to have an error 
of +/- 1° C.  “*” indicates trials run with hairpin sequences; “**” indicates that a 3:1 ratio 
was used for this compound; “---” indicates that no trial has been done. 
 
 
 
    
 
 
DNA  A4T4 A4GT4 A4CT4 A3CT3 A3T3 A4GCT4 (AAG)3 (AT)4 A4 
Native 
Tm (° C) 
55, 
65* 
67 66 66 54, 63* 53 73* 58 69 
G
ro
u
p
 I
 
 
      
DB224 21 18 17 16 >17* 0 6 5 3 
DB232 26 >22 >22 >22 24 14 15 7 3 
DB321 23 23 22 23 5 0 16 5 2 
DB322 28 >25 >23 >22 29 20 8 8 8 
DB323 14 10 10 8 16* 9 6 -2 11 
DB334 27 >23 >21 >21 >25* 6 7 12 8 
DB325 >22 12 12 11 19* 10 5 1 7 
DB496 4 2 2 2 0* 2 2 -2 2 
DB462 13 10 10 7 14* 2 2 3 4 
DB510 4 2 1 2 3* 0 0 0 1 
DB2147 14 --- 0 --- --- 0 1 --- --- 
DB1947** 16 13 14 15 18* 14 9 --- 12 
DB2239 2* 3 2 1 2 1 1 -2 1 
DB2240 13* 10 9 12 11 7 4 1 3 
DB2242 2* 1 --- --- --- 2 --- --- --- 
DB2243 0* 1 --- --- --- 0 --- --- --- 
DB2260 15* 13 13 12 12* 11 5 0 7 
DB2265 12* 2 3  1 2 0 1 0 1 
G
ro
u
p
 I
I 
DB2119 14* 12 11 2 2 2 1 3 1 
DB2120 15* >21 >21 >19 3 9 4 4 2 
DB2148 17 17 17 8 2* 1 2 2 0 
DB2149 11 5 6 3 2* 3 1 --- 2 
DB2150 15* 14 13 13 14* 9 9 0 7 
DB2201 5* 4 --- --- --- 1 2 --- --- 
DB2241 2* 1 --- --- --- 0 --- --- --- 
DB2232 >24* 16 17 16 18 13 9 9 9 
DB2237 17* 9 10 9 13 8 4 -1 5 
DB2238 20* 13 13 11 15 10 6 3 7 
DB2246 20* 14  14 13 17 11 6 3 7 
DB2247 14* 8* 9 6 13* 7 3 -1 4 
 
 
20 
 
 
Many of the larger compounds showed preferences for sequences with two AT-
rich sites, suggesting a two-site binding mode. Group I compounds elevated the melting 
temperature of such sequences the most, with ΔTm values over 22° C. All of the larger 
compounds that showed binding predominantly preferred sequences having two A-
tracts, and had trouble accommodating two intervening GC base pairs. DB1947, a 
smaller compound, bound to the two-site sequences as well as to the others, showing 
little to no selectivity. DB2147 thermally stabilized the A4T4 sequence, but did not do the 
same to any of the other oligonucleotides. When compared to the A4T4 sequence, the 
introduction of alternating AT base pairs, (AT)4, effectively decreased the binding of all 
compounds. Several compounds were ineffective as minor groove binders, including 
DB2242, DB2243, DB2201, the symmetrical compounds in Group III, the larger sulfur-
containing compounds, and the selected cyanine dyes. However, many more 
G
ro
u
p
 I
II
 DB1746 2 0 0 --- --- 2 --- --- --- 
DB1747 3 --- 3 --- --- 0 --- --- --- 
DB1791 15 13 14 13 14 9 5 0 4 
DB2189 2* 1 --- --- --- 2 --- --- --- 
 DB1998 18 13 --- 13 19 11 9 2 9 
G
ro
u
p
 I
V
 
DB1255 17 14 --- 14 16 6 5 2 6 
DB2204 4 4 --- --- 4* 4 --- 3 --- 
DB2224 0 0 ---  --- --- -2 1 -2 --- 
1C-
Linker 
Cyanine 
2 0 --- --- --- 0 --- --- --- 
3C-
Linker 
Cyanine 
2 1 --- --- --- 1 --- --- --- 
5C-
Linker 
Cyanine 
1 1 --- --- --- 0 --- --- --- 
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compounds were found to be strong binders by thermal melting, and show promising 
results. 
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Figure 8. ΔTm graphs for DB224 and DB232 with A4T4. Compounds were tested at 
0:1, 1:1, 2:1, and 3:1 ratios with 3 µM DNA in CCL or MES buffer (100 mM NaCl) at pH 
6.2. DB232, the close analog of DB224, resulted in a more uniform thermal melting 
curve than did the parent compound. The 1:1 ratio of DB224 and A4T4 showed free DNA 
left in solution, while the 1:1 ratio of DB232 and A4T4 did not. 
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Figure 9. ΔTm results for DB224, DB321, DB496, DB510, and analogs. Compounds 
were tested at a 2:1 ratio with 3 µM DNA in CCL or MES buffer (100 mM NaCl) at pH 
6.2. DB224, DB321, DB496, and DB510 bound to nearly all sequences more weakly 
than their analogs, DB232, DB322, DB334, and DB496, which are identical except for 
the inclusion of terminal non-polar groups. DB323, containing no phenyl groups, bound 
more weakly than DB321 to most sequences, exceptions being A4, A3T3, and A4GCT4. 
Compounds predominantly preferred the A4T4 sequence, with most binding with similar 
affinity to the A4GT4, A4CT4, A3CT3, and A3T3 sequences. 
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Figure 10. ΔTm results for remaining Group I compounds. Compounds were tested 
at a 2:1 ratio, with the exception of DB1947, which was tested at a 3:1 ratio. A 
concentration of 3 µM DNA was used in CCL or MES buffer (100 mM NaCl) at pH 6.2. 
Again, compounds predominantly preferred the A4T4 sequence. DB1947, a smaller 
compound, showed little to no specificity. DB2240, containing a six-membered central 
ring with a carbonyl, bound more strongly to all sequences than did DB2239, which 
contains a similar five-membered central ring. DB2260 bound more strongly or the 
same as DB2240, the only difference being the replacement of phenyls by pyridines. 
DB2265, containing a central urea moiety, bound well only to A4T4. 
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Figure 11. ΔTm results for DB2232 and analogs. Compounds were tested at a 2:1 
ratio with 3 µM DNA in CCL or MES buffer (100 mM NaCl) at pH 6.2. DB2232 and 
analogs predominantly preferred the A4T4 and A3T3 sequences. Significant binding also 
occurred with the A4GT4, A4CT4, A3CT3, A3T3, and A4GT4, sequences. Analogs differed 
by the location of methyl groups placed on nitrogen atoms of the flanking 
benzimidazoles. No change in selectivity was observed between the parent compound 
and analogs. DB2232 remained the strongest overall binder. 
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Figure 12. ΔTm results for selected Group II, III, and IV compounds. Compounds 
were tested at a 2:1 ratio with 3 µM or 1 µM DNA in CCL or MES buffer at pH 6.2. 
Similar trends in selectivity were observed for DB2148, DB2150, DB1791, DB1998, and 
DB1255. The A4T4 sequence was generally preferred, followed by A4GT4, A4CT4, 
A3CT3, and A3T3. One notable exception is DB2120; this compound prefers A4GT4 and 
A4CT4 binding sites to A4T4. DB2119 and DB2149 bound to A4T4, but were poor binders 
of the other sequences. 
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3.3 CIRCULAR DICHROISM 
Circular dichrosim experiments were performed to observe induced chirality by 
ligands binding to DNA. Changes in compound chirality can be seen above about 300 
nm, in the compound region of a spectrum, and indicate minor groove binding. Shape 
changes in DNA can be seen below about 300 nm, in the DNA region of a spectrum, 
and indicate that binding alters the conformation of DNA in some way. Examples 
include groove distortion, curvature change, and intercalation. 
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Figure 13. Circular dichroism results for DB224 and DB232 with A4T4. Spectra were 
measured in pH 6.2 CCL buffer (10 mM CCL, 100 mM NaCl, 1 mM EDTA) with a DNA 
concentration of 3 μM. Similar changes in the compound and DNA regions were 
observed for DB224 and DB232 with A4T4; however, the CD of DB232 was saturated at 
2:1 while that of DB224 was saturated at 4:1. DB232 also exhibited a larger induced CD 
in the DNA region than did DB224, but both spectra indicate some change in DNA 
structure upon binding. Both compounds show a dramatic induced CD in the compound 
region, indicating minor groove binding, and saturated at similar intensities despite the 
different saturating ratios.  
 
 
 
 
 
 
27 
 
-30
-20
-10
0
10
20
240 280 320 360 400 440 480
CD of DB321 and A
4
GT
4
DNA
0.5:1
1:1
1.5:1
2:1 
2:1 (anealed)
C
D
 (
m
d
e
g
)
Wavelength (nm)       
-30
-20
-10
0
10
20
240 280 320 360 400 440 480
Annealed CD of DB321 and A
4
GT
4
DNA
1:1
2:1
3:1
C
D
 (
m
d
e
g
)
Wavelength (nm)  
Figure 14. Circular dichroism results for DB321 with A4GT4. Spectra were measured 
in pH 6.2 CCL buffer (10 mM CCL, 100 mM NaCl, 1 mM EDTA) with a DNA 
concentration of 3 μM.The spectra marked “annealed” are from samples that were 
removed from the instrument and annealed prior to scanning. Initially, DB321 did not 
appear to have induced CD for the A4GT4 sequence; however, when the samples were 
annealed prior to being tested, DB321 induced a large CD in the compound and DNA 
regions of the spectra, indicating minor groove binding and some change to DNA 
structure upon binding. DB321 saturated the CD spectrum at a ratio of approximately 
3:1. 
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Figure 15. Circular dichroism results for DB334 with A4T4. Spectra were measured 
in pH 6.2 CCL buffer (10 mM CCL, 100 mM NaCl, 1 mM EDTA) with a DNA 
concentration of 3 μM. The CD of DB334 with A4T4 shows a dramatic positive and 
negative induced CD in the compound region, indicating minor groove binding. A large 
induced CD is also visible in the DNA region, indicating significant DNA structural 
changes upon binding. DB334 saturated the CD spectra at a ratio of approximately 
3.2:1. 
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Figure 16. Circular dichroism results for DB2260 with A4T4. Spectra were measured 
in pH 6.2 CCL buffer (10 mM CCL, 100 mM NaCl, 1 mM EDTA) with a DNA 
concentration of 3 μM. The CD of DB2260 with A4T4 shows a large positive and 
negative induced CD in the compound region, indicating minor groove binding. A 
smaller induced CD is visible in the DNA region, indicating structural changes to the 
DNA upon binding. DB2260 saturated the CD spectra at a ratio of approximately 4.4:1.  
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Figure 17. Circular dichroism results for DB2150 with A4T4. Spectra were measured 
in pH 6.2 CCL buffer (10 mM CCL, 100 mM NaCl, 1 mM EDTA) with a DNA 
concentration of 3 μM. The CD of DB2150 with A4T4 shows an induced CD in the 
compound and DNA regions, indicating minor groove binding and some structural 
changes to the DNA upon binding. DB2150 saturated the CD spectra at a ratio of 
approximately 2:1. 
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Figure 18. Circular dichroism results for DB2120 with A4GT4. Spectra were 
measured in pH 6.2 CCL buffer (10 mM CCL, 100 mM NaCl, 1 mM EDTA) with a DNA 
concentration of 3 μM. The CD of DB2120 with A4GT4 shows an induced CD in both the 
compound and DNA region, indicating minor groove binding and structural changes to 
the DNA upon binding. DB2120 saturated the CD spectra at a ratio of approximately 
3.5:1. 
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Figure 19. Circular dichroism results for DB2232 with A4T4. Spectra were measured 
in pH 6.2 CCL buffer (10 mM CCL, 100 mM NaCl, 1 mM EDTA) with a DNA 
concentration of 3 μM. The CD of DB2232 with A4T4 shows an induced CD in the 
compound and DNA regions, indicating minor groove binding and structural changes to 
the DNA upon binding. DB2232 saturated the CD spectra at a ratio of approximately 
2.8:1. 
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Figure 20. Circular dichroism results for DB1791 with A4T4. Spectra were measured 
in pH 6.2 CCL buffer (10 mM CCL, 100 mM NaCl, 1 mM EDTA) with a DNA 
concentration of 3 μM. The CD of DB1791 with A4T4 shows significant induced CD in 
the compound region, indicating minor groove binding. A dramatic induced CD is visible 
in the DNA region of the spectrum, indicating significant DNA structural changes upon 
binding. DB1791 saturated the spectra at a ratio of approximately 1.6:1. 
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Figure 21. Circular dichroism results for DB1998 with A4T4. Spectra were measured 
in pH 6.2 CCL buffer (10 mM CCL, 100 mM NaCl, 1 mM EDTA) with a DNA 
concentration of 3 μM. The CD of DB1998 with A4T4 shows both positive and negative 
induced CD in the compound region, indicating minor groove binding. A smaller induced 
CD is visible in the DNA region, indicating some structural change to the DNA upon 
binding. DB1998 saturated the spectra at a ratio of approximately 1.6:1. 
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Table 3. Approximate saturating ratios for CD experiments. Spectra were measured 
in pH 6.2 CCL buffer (10 mM CCL, 100 mM NaCl, 1 mM EDTA) with a DNA 
concentration of 3 μM. DB232 saturated at a much lower ratio than did its analog 
DB224, which suggests that DB232 is a stronger binding compound. DB321 and its 
analog, DB334, saturated the spectra of different sequences at similar ratios; however, 
the samples of DB321 were annealed between each titration. DB2150, DB1791, and 
DB1998 all saturated at or below approximately a 2:1 ratio, suggesting that these 
compound are relatively strong binders. DB2120 saturated at about 3.5:1, DB2232 
saturated at about 2.8:1, and DB2260 saturated at a high ratio of approximately 4.4:1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound Sequence Appx. Saturating Ratio 
DB224 A4T4 3.8-4.2 
DB232 A4T4 1.8-2.2 
DB321 A4GT4 2.8-3.2 
DB334 A4T4 3-3.4 
DB2260 A4T4 4.2-4.6 
DB2150 A4T4 1.8-2.2 
DB2120 A4GT4 3.3-3.7 
DB2232 A4T4 2.6-3 
DB1791 A4T4 1.4-1.8 
DB1998 A4T4 1.4-1.8 
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3.4 MASS SPECTROMETRY 
Mass spectrometry experiments were performed to determine the stoichiometry 
of binding. Multiple DNA sequences were tested together with a single compound for 
speed and qualitative assessment of relative binding.  
 
 
Figure 22. Mass spectrometry results for DB224. Samples containing 5 μM of each 
oligonucleotide were tested in 150 mM ammonium acetate buffer with a capillary 
voltage of 2.5 kV, cone voltage of 30 V, source block temperature of 70° C, desolvation 
temperature of 100° C, nitrogen as the nebulizing and drying gas, and direct injection at 
5 μL/min. Using MassLynx 4.1 software, the observed mass of each equivalent species 
was multiplied by its charge and the areas were added to give a single peak at the 
“parent” mass. Ratios are reported as [compound]:[each oligonucleotide]; samples were 
prepared from the same pre-mixed DNA stock solution.  DB224 bound as a monomer to 
A4T4 and A4GT4. No complex is visible for A4GCT4, which is in agreement with the Tm 
data. This result shows that mass spectrometry is an excellent method to determine 
binding stoichiometry, and can also be used as a qualitative comparison for major 
differences in binding affinity. 
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Figure 23. Mass spectrometry with and without methanol. Samples containing 5 μM 
of each oligonucleotide were tested in 150 mM ammonium acetate with and without 5% 
methanol (v/v) buffer, with a capillary voltage of 2.5 kV, cone voltage of 30 V, source 
block temperature of 70° C, desolvation temperature of 100° C, nitrogen as the 
nebulizing and drying gas, and direct injection at 5 μL/min. Using MassLynx 4.1 
software, the observed mass of each equivalent species was multiplied by its charge 
and the areas were added to give a single peak at the “parent” mass. Ratios are 
reported as [compound]:[each oligonucleotide]; all samples were prepared from the 
same pre-mixed DNA stock solution. DB232 bound as a monomer to A4T4, A4GT4, and 
A4GCT4. DB2150 also bound as a monomer to A4T4, A4GT4, and A4GCT4. In all cases, 
the samples tested with 5% methanol resulted in a better signal-to-noise ratio. The 
complex of DB232 with A4GCT4 was only visible in the spectrum taken with methanol. 
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Figure 24. Mass spectrometry results for DB334, DB2120, DB2232, and DB2238. 
Samples containing 5 μM of each oligonucleotide were tested in 150 mM ammonium 
acetate/5% methanol (v/v) buffer with a capillary voltage of 2.5 kV, cone voltage of 30 V, 
source block temperature of 70° C, desolvation temperature of 100° C, nitrogen as the 
nebulizing and drying gas, and direct injection at 5 μL/min. Using MassLynx 4.1 
software, the observed mass of each equivalent species was multiplied by its charge 
and the areas were added to give a single peak at the “parent” mass. Ratios are 
reported as [compound]:[each oligonucleotide]; all samples were prepared from the 
same pre-mixed DNA stock solution. DB334 bound as a monomer to A4T4 and A4GT4, 
but no complex was visible with A4GCT4. DB2120 bound as a monomer to A4GT4, but 
no complex was visible with A4T4 or A4GCT4. This is in agreement with the selectivity of 
DB2120 shown via thermal melting experiments. DB2232 bound as a monomer to A4T4, 
A4GT4, and A4GCT4. DB2238 bound as a monomer to A4GT4 and A4T4, but no complex 
was visible with A4GCT4 
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Table 4: Summary of mass spectrometry results. Samples containing 5 μM of each 
oligonucleotide and a 6:1 ratio of [compound]:[each oligonucleotide] were tested in 150 
mM ammonium acetate with or without 5% methanol (v/v) buffer. “1:1” indicates 
monomeric binding; “0 “ indicates that no complex was formed. Monomeric complexes 
were observed for DB224 with A4T4 and A4GT4; for DB232 with A4T4, A4GT4, and 
A4GCT4; for DB334 with A4T4 and A4GT4; for DB2120 with A4GT4; for DB2150 with A4T4, 
A4GT4, and A4GCT4; for DB2232 with A4T4, A4GT4, and A4GCT4; and for DB2238 with 
A4T4 and A4GT4. No 2:1 complexes were observed. 
 
 
 
 
 
 
 
 
3.5 SURFACE PLASMON RESONANCE 
Surface plasmon resonance studies were performed for determination of binding 
constants. Several compounds were tested via SPR with HEPES buffer; however, these 
large compounds resulted in significant streptavidin-surface binding. MES buffer gave 
better results for a few cases, and was used instead for all surface plasmon resonance 
studies. Many of the compounds in Groups I and II were tested in this manner, but most 
resulted in unpresentable sensorgams due to streptavidin-surface binding, aggregation, 
and general “sticky” compound properties. 
 
 A4T4 A4GT4 A4GCT4 
DB224 1:1 1:1 0 
DB232 1:1 1:1 1:1 
DB334 1:1 1:1 0 
DB2120 0 1:1 0 
DB2150 1:1 1:1 1:1 
DB2232 1:1 1:1 1:1 
DB2238 1:1 1:1 0 
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Figure 25. SPR Sensorgrams for DB2150. Samples were prepared and tested in pH 
6.2 MES buffer (0.005% P20, v/v) at various ratios from 5 nM to 500 nM. Data was 
collected using a Biacore 2000 optical biosensor instrument. 
 
 
 
 
 
Figure 26. SPR Steady-State Fits for DB2150. Samples were prepared and tested in 
pH 6.2 MES buffer (0.005% P20, v/v) at various ratios from 5 nM to 500 nM. Data was 
collected using a Biacore 2000 optical biosensor instrument. DB2150 bound with similar 
affinity to A4T4, A4GT4, and A4GCT4, with binding constants of 7.1 x 10
7, 6.4 x 107, and 
average binding constant of 9.1 x 106 respectively. The dimeric binding to A4GCT4 
showed negative cooperatively. The stoichiometric values used to for data fitting were 
based on the predicted maximum RU values for the different sequences.  
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MOLECULAR MODELING 
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Figure 27. Electrostatic potential maps for minimum energy conformers of DB224, 
DB321, and analogs. Maps were generated by Spartan ’04 using a Hartree-Fock 
model with a 6-31G* basis set to determine the conformation with Emin. Red indicates 
regions of negative electrostatic potential, green indicates hydrophobic regions, and 
blue indicates regions of positive electrostatic potential. Note the increased hydrophobic 
surfaces in DB232, DB322, and DB334.  
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Figure 28. Electrostatic potential maps for minimum energy conformers of DB496, 
DB510, and analogs. Maps were generated by Spartan ’04 using a Hartree-Fock 
model with a 6-31G* basis set to determine the conformation with Emin. Red indicates 
regions of negative electrostatic potential, green indicates hydrophobic regions, and 
blue indicates regions of positive electrostatic potential. Note the increased hydrophobic 
surfaces in DB325 and DB462. 
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Figure 29. Electrostatic potential maps for minimum energy conformers of 
selected Group I compounds. Maps were generated by Spartan ’04 using a Hartree-
Fock model with a 6-31G* basis set to determine the conformation with Emin. Red 
indicates regions of negative electrostatic potential, green indicates hydrophobic 
regions, and blue indicates regions of positive electrostatic potential. The geometry of 
DB2240 appears drastically changed when compared to DB2239. DB2260 is very 
similar to DB2240, but DB2265 is almost linear. 
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Figure 31. Electrostatic potential maps for minimum energy conformers of 
DB2232 and analogs. Maps were generated by Spartan ’04 using a Hartree-Fock 
model with a 6-31G* basis set to determine the conformation with Emin. Red indicates 
regions of negative electrostatic potential, green indicates hydrophobic regions, and 
blue indicates regions of positive electrostatic potential. Note the steric hindrance to 
binding caused by the introduction of methyl groups onto the flanking benzimidazoles.  
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Figure 32. Electrostatic potential maps for minimum energy conformers of 
selected Group II compounds Maps were generated by Spartan ’04 using a Hartree-
Fock model with a 6-31G* basis set to determine the conformation with Emin. Red 
indicates regions of negative electrostatic potential, green indicates hydrophobic 
regions, and blue indicates regions of positive electrostatic potential. DB2119 and 
DB2120 have different minimized conformations despite their structural similarity. 
DB2148 and DB2119 both show the central ring twisted out of the plane created by the 
flanking groups. DB2150 was modeled as a trication, and as such has enhanced 
electropositive potential. The model of DB2201 shows a conformation inconsistent with 
typical minor groove binders due to the geometry of the ether linkages. This 
conformation is in stark contrast to that of DB2120, which differs only by the inclusion of 
two methylene groups. 
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4 DISCUSSION 
 
4.1 DNA Microstructure 
Poly-dA oligonucleotides such as A4T4 are more highly curved than mixed 
sequences.4-5 The minor groove narrows relative to sequences containing GC BPs,16 
but less so for sequences containing multiple AT steps.6 The bases also take on a 
propeller twist in A-tracts.4, 16 The narrowed minor groove allows stronger contacts with 
groove-binders and greater negative electrostatic potential.4-6 The combination of these 
forces accounts for the overarching binding preferences evident most clearly in Group I 
compounds.  
Since mixed A-T sequences take on A-tract characteristics to a lesser extent, 
compounds with a high affinity for A4T4 bind to (AT)4 with a lower K and a less favorable 
ΔG. Alternating A-T sequences also tend to have overwound helices compared to 
mixed sequence B-DNA, which has a helix repeat of about 10.5 BPs per turn.4-5, 17  In 
the case of poly-dAT or poly-dAAT sequences, a D-DNA has been observed, which has 
a helix repeat of about 8 BPs per turn; but alternating A-T sequences are quite 
polymorphic. None of the compounds tested were able to bind to the (AT)4 sequence 
with much success. Introduction of GC base pairs in the middle of the binding region 
causes the DNA to adopt a wider minor groove and a more regular curvature, a bad fit 
for conformationally locked compounds. A longer linker could solve this problem; 
however, some structural rigidity should be maintained if the compound is to be 
selective.  
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The ΔTm results indicate that the sequence A4GCT4 is quite different from A4GT4 
and A4CT4, which have many similarities with A4T4. Two GC BPs effectively disrupt the 
A-tract curvature and present a large steric hindrance to binding in the form of exocyclic 
amines in the minor groove. Most of the compounds tested did not bind well to the A4 
single-site control sequence in the minor groove, which indicates that the longer, two-
site binding sequence is required. The (AAG)3 site was also challenging to recognize. 
Having only two AT BPs on either side of a GC BP decreased minor groove 
electrostatic potential and binding affinity of compounds. Once a successful paradigm is 
developed for GC recognition, such a complex sequence should be recognizable.  
 
4.2 Group I Compounds 
 Minor groove binders typically have a characteristic crescent shape,4 a motif that 
holds true for many of the examined compounds. Evident from the molecular models 
(Figures 28-32), many of the relatively rigid compounds in Group I are slightly more 
curved than most. Their limited accessible conformations cause tighter than normal 
curvatures, providing the physical basis for these compounds’ specificity of binding. 
Binding of any ligand to the minor groove is expected to decrease the number of 
available conformations accessible to the DNA. It follows that a more conformationally 
limited ligand will result in a more conformationally limited complex, and that a more 
rigid compound could mean a greater entropic loss by DNA upon binding. However, this 
conformational entropic loss should be somewhat offset by the release of water from the 
minor groove. 
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 Compounds in Group I which were able to significantly bind to A4GT4 and A4CT4 
( Tm > 10 ºC) did so with a similar or lessened affinity compared to A4T4, indicating that 
the hydrogen bond acceptors in the linker region are most likely not binding to the 
amine of guanine. Interestingly, the larger compounds from Group I, such as DB232 
and DB321, showed very low affinity for smaller sequences such as A4. Again, this 
selectivity suggests the two-site binding mode for these compounds. Also, since DB321 
could bind well to A3CT3 but not to A3T3, this particular compound may require a binding 
site at least seven base pairs long. DB2147 bound well only to the A4T4 sequence. This 
compound is extremely curved, so the inclusion of even one GC base pair may have 
relaxed the minor groove curvature enough to make DB2147 a bad fit. 
 The terminal amidine-isopropyl or amidine-cyclopentane analogs (DB232, 
DB322, DB235, DB334, and DB462) bound with a greater thermal melting point 
elevation than their parent, terminal-amidine compounds (DB224, DB321, DB496, and 
DB510). These analogs, containing non-polar amidine extensions, experience 
increased binding in a non-specific manner. Such an inclusion would likely do the same 
for many minor groove binders. Shown in Figure 13, the CD of DB232 with A4T4 
saturated at a much lower ratio than did DB224 (Table 3), again, suggesting increased 
binding affinity. Although DB510 is extremely close in structure to DB462, it showed 
very little change in thermal melting temperature for any sequence, indicating that the 
flanking isopropyl groups are essential to the binding of this structure. Likewise, DB496 
showed almost no binding affinity, whereas DB325 dramatically increased the thermal 
melting temperature of many sequences. This increased DNA affinity is most likely due 
to van der Waals interactions between the non-polar amidine extension and the 
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deoxyribose of the DNA. The increased van der Waals surfaces can clearly be seen 
from the electrostatic potential maps. The molecular models also suggest that the 
positive charge on the amidine groups becomes partially dispersed through the non-
polar extensions. Such a change may decrease the Gibb’s energy necessary for 
compound dissolution for DB224 and DB321, as the interaction between the positive 
terminals and the central hydrogen bond acceptor would be decreased. Indeed, the 
circular dichrosim results for DB321 (Figure 14) and DB334 (Figure 15) as well as the 
thermal melting results for DB224 and DB232 with A4T4 (Figure 8) suggest that the 
inclusion of terminal cyclopentane groups may have decreased stacking effects. 
Specifically, the inclusion of terminal cyclopentane groups in DB334 eliminated the need 
to anneal between CD titrations, shown for DB321 in Figure 14.  
  The molecular modeling results suggest that many of the linkers, designed to 
accept a hydrogen bond from guanine, may actually be shielded within the molecule 
and inaccessible due to the flanking phenyl rings. Because of this structural feature, 
DB2239 and DB2240 were synthesized and are notable exceptions, with the carbonyl 
group protruding to a more easily accessible location. DB2240, which contains a six-
membered central ring, is a stronger binding compound than DB2239, which contains a 
five-membered central ring. The models show that the change from a six-membered to 
a five-membered central ring has a profound effect on the geometry of the ligand, with 
the central ring of DB2239 lying in the plane created by the flanking phenyl-
benzimidazole groups, and the central ring of DB2240 twisting out of the plane created 
by the flanking phenyl-benzimidazole groups. This structural difference can clearly 
explain the difference in melting point elevation. Paramount to GC recognition will be 
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the accessibility of a hydrogen bond acceptor group. A comparison between DB323 and 
DB334 indicates that the phenyl ring does contribute significantly to binding for all 
sequences except A4; however, this ring probably interacts in a weakly specific manner 
to AT BPs, and presents a structural feature that may be changed for greater specificity. 
By replacing the phenyl with a smaller group, such as an alkyl ether, ethyl, or amide, 
other hydrogen bond accepting groups could become available. The replacement of the 
phenyl groups in DB2240 by pyridine groups in DB2260 causes an increase in binding, 
notably to the A4GCT4 sequence. This may be due to decreased steric hindrance, as 
adjacent hydrogens of the phenyl groups which face the minor groove are effectively 
eliminated with this substitution.  
 
4.3 Group II Compounds 
Thermal melting results suggest that Group II compounds generally do not bind 
as well as Group I compounds to the favored sequences. Perhaps due to increased 
flexibility and ability to fold back on themselves, many Group II compounds also appear 
to be more able to accommodate the single site sequence when compared to the two-
site sequences containing one GC BP. For example, DB2150, DB2232, DB2237, 
DB2238, and DB2246 all elevate the thermal melting point of the A4GT4 sequence only 
4-7 ºC more than the A4 sequence, compared to DB224, DB232, DB321, DB322, and 
DB334, which elevate the A4GT4 sequence 15-21 ºC more than the A4 sequence. The 
ability to take on a secondary binding mode where each AT site accommodates one 
folded-back compound, if indeed present, presents a serious challenge to selectivity. 
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DB2148 is one interesting exception to this lack of selectivity. Perhaps due to the 
electrostatic potential of the DNA sequences, this compound does not bind well to any 
sequence other than A4T4, A4GT4 and A4CT4. DB2119 exhibits similar selectivity; 
however, the analog DB2120 is strikingly selective for sequences with a single G or C, 
elevating the thermal melting point of A4GT4 and A4CT4 over 21 °C. The molecular 
modeling results for DB2119 and DB2120 (Figure 32) indicate significantly different 
minimized structures, with the central phenyl of DB2119 twisting out of the plane 
created by the flanking phenyl-benzimidazole groups, and the central pyridine of 
DB2120 lying in plane with the flanking phenyl-benzimidazole groups. This is likely a 
contributing factor to their differences in selectivity. Although DB2120 shows significant 
binding to the A4T4 sequence (ΔTm of 15 °C), this compound is an excellent lead for the 
development of linkers capable of recognizing one or two GC BPs. DB2120 combines a 
central aromatic ring with flexible linkers, which perhaps allow the adjacent hydrogens 
of the phenyl groups enough room to prevent steric clashes. 
DB2150 binds with a similar affinity to A4T4 and A4GT4, and with a slightly 
lessened binding affinity to A4GCT4. These SPR results are reinforced by the ΔTm 
results; however, the mass spectrometry and SPR results are not in good agreement as 
to the stoichiometry of the DB2150 and A4GCT4 complex (Figures 23 and 26). Mass 
spectrometry indicates a 1:1 complex, while SPR indicates a 2:1 complex. This 
discrepancy can be explained by the negative cooperativity shown via SPR. Since the 
first binding constant is significantly higher than the second, the second molecule may 
be binding through non-specific interactions. DB2150 is assumed to be a trication in 
solution, and the dimeric complex may be too unstable to enter the gas phase, even 
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using ESI mass spectrometry. The monomeric complex would be more stable, thus 
visible by mass spectrometry.  
The N-CH3 substituted benzimidazole analogs of DB2232 were developed in an 
effort to understand the effects of the protonation states of the benzimidazoles on 
affinity and selectivity. The results suggest no change in selectivity, only decreases in 
binding most likely due to steric effects and a loss in the ability to act as hydrogen bond 
donors. Interestingly, the mass spectrometry results for DB2232 (Figure 24) show only 
monomeric complexes with A4T4, A4GT4, and A4GCT4. This is in stark contrast with a 
previously reported dimer that forms with the sequence AATTGCAATT.18 The proposed 
binding model involved RT546 (DB2232) folding back on itself and binding one folded 
molecule to each AATT site. Because the minor groove of AATT sites is wider relative 
to A4 sites, DB2232 may not be able to fit in such a narrowed minor groove when folded 
back. The discrepancy between the monomeric and dimeric results may arise from 
specific properties inherent with flanking A4 sites; perhaps this tightened minor groove 
must be wedged apart for even monomeric binding to occur. 
 
4.4 Group III Compounds 
The symmetrical Group III compounds (DB1746, DB1747, and DB2289) proved 
to be poor binders of any sequences tested. This suggests that the phenyl-
benzimidazole-amidine terminals are much preferred to the phenyl-furan-phenyl-
amidine terminals. However, the results from DB1791 indicate that the inclusion of at 
least one phenyl-furan-phenyl-amidine terminal does have potential as a structural 
motif. Interestingly, the circular dichroism results (Figure 20) indicate a significant 
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structural change in the DNA (A4T4) upon binding of DB1791. This could be due to the 
compound folding back on itself, wedging the minor groove apart upon the binding of 
one or two molecules. Other explanations include significant DNA curvature change, or 
partial intercalation. If DB1791 is folding back on itself, then the larger, symmetric 
compounds may also be folding back on themselves. These compounds (DB1746, 
DB1747, and DB2289) would form larger structures than DB1791 if folded back. The 
binding sites may not be able to accommodate a larger structure than DB1791, 
especially considering the large structural changes already visible in the CD of DB1791 
and A4T4 (Figure 20). The symmetrical compounds, if folded back, would also put the 
terminal, positively charged amidines closer to each other, which is unfavorable. 
If DB1791 either induces a DNA curvature change or partially intercalates, given 
that only this asymmetric compound binds well out of this group, such a structural 
change may be feasible only once in the entire binding site. If this change in structure 
were repeated twice, in close proximity, it could distort the geometry of the DNA to the 
extent of forming an unstable structure with far from optimal stacking interactions. Such 
a structure would not be thermodynamically favored, and so a more likely interaction 
would be only one of the terminals of the symmetric Group III compounds binding. 
However, if only one of the terminals of DB1746, DB1747, or DB2289 were bound, this 
would also result in an unstable complex, and the compound would be 
thermodynamically driven away from minor groove binding. 
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4.5 Group IV Compounds 
Most of the compounds in Group IV also proved to be poor two-site binders. 
Previously, the replacement of a furan by a thiophene in DB818 was reported to 
dramatically increase minor groove binding.3c However, the inclusion of two such large 
atoms as sulfur in the ring systems may present a steric obstacle to minor groove 
binding, specific to larger compounds. Another possibility is that the curvature of the 
large Group IV compounds is not a good match for the curvature of the minor groove. 
DB2224 actually destabilized duplex DNA, implying that this compound binds to single 
stranded DNA better than to double stranded DNA. The cyanine dyes that were 
selected do not contain any hydrogen bond donors, which is likely one reason they were 
only able to bind weakly to the tested sequences. The selected cyanine dyes also 
contain N-CH3 groups, which may act as steric hindrances to deep minor groove 
binding. Two of the compounds, DB1255 and DB1998, show some promise as minor 
groove binders, and may even be able to accommodate two GC base pairs in the two-
site model. However, these compounds are also small, and lack the sequence 
specificity required.  
 
5 CONCLUSIONS 
Significantly more information about two-site minor groove binders has been 
discovered through this work. Since Group I compounds appear to be the strongest 
binders of A4T4, A4GT4, and A4CT4, slight rigidity or aromaticity in the linker may 
promote binding. Group II compounds also show good potential, although in general the 
flexible linker may cause specificity to be more challenging to obtain. The phenyl-
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benzimidazole-amidine terminal is another characteristic indicative of increased binding 
affinity, as well as non-polar amidine extensions. 
New ideas have also been developed for compound selectivity and GC 
recognition. Additional compounds should be developed with conservation of the 
benzimidazole-amidine terminal, substituting the phenyls for smaller, more sequence-
specific groups. In order to distinguish between A4T4 and A4GT4 or A4CT4, more linkers 
should be designed capable of accepting a hydrogen bond from the protruding amine 
group of guanine. Replacement of the phenyl moieties by smaller groups may allow 
such an acceptor to become accessible, and successful hydrogen bond formation could 
provide a basis for selectivity of A4GCT4, A4GT4 or A4CT4 over A4T4. The design of a 
compound able to bind A4GCT4 should include these same characteristics; however, 
such a compound must have a longer linker and be more able to accommodate the 
widening of the minor groove and decrease in electrostatic potential such a sequence 
creates. Additionally, there is a greater chance for compounds to fold back on 
themselves when the AT sites have more separation. Based on this study, jumping two 
GC BPs has already proven to be more difficult than jumping one. 
Progress for GC selectivity has already been made. DB2120 is selective for 
sequences containing one intervening GC BP, and this discovery marks a significant 
step in the development of a new, programmable molecular language for sequence 
specific minor groove binding compounds. Additionally, replacement of phenyls by 
pyridines in DB2260 hints of increased GC selectivity, but this should be explored more 
to determine if such a substitution promotes GC binding with other linking moieties.  
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Challenges have included limited selectivity among the two-site compounds, and 
difficulty in studying these large molecules via SPR. There is also a lack of structural 
information to discern any of the specific binding interactions of these compounds. NMR 
or crystallographic studies would open the door to more intelligent compound 
engineering, and a complex with DB2120 would be a good candidate for such work. 
A variety of compounds have now been found which bind with a two-site mode. 
The next step is the development of better linkers capable of GC recognition, and 
DB2120 is a good lead compound for this work. By incorporating other structural motifs 
that were found to increase binding, (i.e. terminal isopropyl groups, terminal 
cyclopentane groups, substitution of phenyls by pyridines), stronger binding analogs 
with this capability are becoming a tangible goal. 
 
 
REFERENCES 
1. (a) Doss, R. M.; Marques, M. A.; Foister, S.; Chenoweth, D. M.; Dervan, P. B., 
Programmable Oligomers for Minor Groove DNA Recognition. Journal of the American 
Chemical Society 2006, 128, 9074-9079; (b) Liu, Y.; Jaiswal, A.; Poggi, M.; Wilson, W. 
D., Surface Plasmon Resonance and Quartz Crystal Microbalance Methods for 
Detection of Molecular Interactions. In Chemosensors: Principles, Strategies, and 
Applications, 1 ed.; Wang, B.; Anslyn, E. V., Eds. John Wiley & Sons, Inc.: 2011; pp 
329-343. 
 
 
58 
2. (a) Dabrowiak, J. C., Metals in Medicine. Wiley: West Sussex, 2009; (b) Nguyen, 
B.; Tanious, F. A.; Wilson, W. D., Biosensor-surface Plasmon Resonance: Quantitative 
Analysis of Small Molecule-nucleic Acid Interactions. Methods 2007, 42, 150-161. 
3. (a) Rahimian, M.; Kumar, A.; Say, M.; Bakunov, S. A.; Boykin, D. W.; Tidwell, R. 
R.; Wilson, W. D., Minor Groove Binding Compounds That Jump a GC Base Pair and 
Bind to Adjacent AT Base Pair Sites. Biochemistry 2009, 41, 1573-1583; (b) Roy 
Chowdhury, A.; Bakshi, R.; Wang, J.; Yildirir, G.; Liu, B.; Pappas-Brown, V.; Tolun, G.; 
Griffith, J. D.; Shapiro, T. A.; Jensen, R. E.; Englund, P. T., The Killing of African 
Trypanosomes by Ethidium Bromide. PLoS Pathog 2010, 6 (12), e1001226; (c) Wilson, 
W. D.; Nguyen, B.; Tanios, F. A.; Mathis, A.; Hall, J. E.; Stephens, C. E.; Boykin, D. W., 
Dications That Target the DNA Minor Groove: Compund Design and Preparation, DNA 
Interactions, Cellular Distribution and Biological Activity. Current Medicinal Chemistry 
Anti-Cancer Agents 2005, 5, 389-408. 
4. Nucleic Acids in Chemistry and Biology. 2 ed.; Oxford University Press: New 
York, 1996. 
5. Sinden, R. R., DNA Structure and Function. Academic Press, Inc.: San Diego, 
CA, 1994. 
6. (a) Lindemose, S.; Nielsen, P. E.; Hansen, M.; Møllegaard, N. E., A DNA Minor 
Groove Electronegative Potential Genome Map Based on Photo-chemical Probing. 
Nucleic Acids Research 2011; (b) Biship, E. P.; Rohs, M.; Parker, S. C. J.; West, S. M.; 
Liu, P.; Mann, R. S.; Honig, B.; Tullius, T. D., A Map of Minor Groove Shape and 
Electrostatic Potential from Hydroxyradical Cleavage Patterns of DNA. ACS Chemical 
Biology 2011, 6, 1314-1320. 
 
 
59 
7. (a) Gregson, S. J.; Howard, P. W.; Gullick, D. R.; Hamaguchi, A.; Corcoran, K. 
E.; Brooks, N. A.; Hartley, J. A.; Jenkins, T. C.; Patel, S.; Guille, M. J.; Thurston, D. E., 
Linker Length Modulates DNA Cross-Linking Reactivity and Cytotoxic Potency of C8/C8' 
Ether-Linked C2-exo-Unsaturated Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) Dimers. 
Journal of Medicinal Chemistry 2004, 47, 1161-1174; (b) Rosado, H.; Rahman, K. M.; 
Feuerbaum, E.-A.; Hinds, J.; Thurston, D. E.; Taylor, P. W., The Minor Groove-binding 
Agent ELB-21 Forms Multiple Interstrand and Intrastrand Covalent Cross-links with 
Duplex DNA and Displays Potent Bactericidal Activity Against Methicillin-resistant 
Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 2011. 
8. Tanada, M.; Sasaki, S., Discrimination of the Length of Two Remote Binding 
Sites by the Spacer-linked DNA Minor Groove Binders. Nucleic Acids Symposium 
Series No. 49 2005, 1-2. 
9. (a) Hawekins, C. A.; Baird, E. E.; Dervan, P. B.; Wemmer, D. E., Analysis of 
Hairpin Polyamide Complexes Having DNA Binding Sites in Close Proximity. Journal of 
the American Chemical Society 2002, 124, 12689-12696; (b) Marques, M. A.; Doss, R. 
M.; Foister, S.; Dervan, P. B., Expaning the Repertoire of Heterocycle Ring Pairs for 
Programmable Minor Groove DNA Recognition. Journal of the American Chemical 
Society 2004, 126, 10339-10349; (c) Weyermann, P.; Dervan, P. B., Recognition of Ten 
Base Pairs of DNA by Head-to-Head Hairpin Dimers. Journal of the American Chemical 
Society 2002, 124, 6872-6878. 
10. (a) Trauger, J. W.; Baird, E. E.; Dervan, P. B., Recognition of 16 Base Pairs in 
the Minor Groove of DNA by a Pyrrole-Imidazole Polyamide Dimer. Journal of the 
American Chemical Society 1998, 120 (3534-3535); (b) Trauger, J. W.; Baird, E. E.; 
 
 
60 
Mrksich, M.; Dervan, P. B., Extension of Sequence-Specific Recognition in the Minor 
Groove of DNA by Pyrrole-Imidazole Polyamids to 9-13 Base Pairs. Journal of the 
American Chemical Society 1996, 118, 6160-6166. 
11. (a) Cordonnier, M.-H. D.; Hilderbrand, M.-P.; Baldeyrou, B.; Lansiaux, A.; 
Keuser, C.; Benzshawel, K.; Lemster, T.; Pindur, U., Deisgn, Synthesis and Biological 
Evaluation of New Oligopyrrole Carboxyamides Linked with Tricyclic DNA-intercalators 
as Potential DNA Ligand or Tomoisomerase Inhibitors. European Journal of Medicinal 
Chemistry 2007, 42, 752-771; (b) Zhang, R.; Wu, X.; Guziec, L. J.; Guziec, F. S.; Chee, 
G.-L.; Yalowich, J. C.; Hasinoff, B. B., Design, Synthesis and Biological Evaluation of a 
Novel Series of Anthapyrazoles Linked with Netropsin-like Oligopyrrole Carboxamides 
as Anticancer Agents. Bioorganic & Medicinal Chemistry 2010, 18, 3974-3984; (c) 
Waring, M.; Bailly, C., DNA Recognition by Intercalators and Hybrid Molecules. Journal 
of Molecular Recognition 1994, 7, 109-122. 
12. Mirkin, S., Expandible DNA Repeats and Human Disease. Nature 2007, 447, 
932-940. 
13. Wilson, W. D.; Tanious, T. A.; Fernandez-Saiz, M.; Rigl, C. T., Evaluation of 
Drug-Nucleic Acid Interactions by Thermal Melting Curves. In Methods in Molecular 
Biology Vol. 90: Drug-DNA Interaction Protocols, Fox, K. R., Ed. Humana Press Inc.: 
Totowa, 1997. 
14. (a) Tanious, F. A.; Nguyen, B.; Wilson, W. D., Biosensor-Surface Plasmon 
Resonance Methods for Quantitative Analysis of Biomolecular Interactions. In Methods 
in Cell Biology, Elsevier Inc.: 2008; Vol. 84, pp 53-77; (b) Wilson, W. D., Analyzing 
Biomolecular Interactions. Science 2002, 295, 2103-2105. 
 
 
61 
15. Spartan '04 Wilndows Tutorial and User's Guide. Wavefunction, Inc.: Irvine, 
2004. 
16. Neslon, H. C. M.; Finch, J. T.; Luisi, B. F.; Klug, A., The Structure of an 
Oligo(dA)-oligo(dT) Tract and its Biological Implications. Nature 1987, 330, 221-226. 
17. Bansal, M., DNA Structure: Revisiting the Watson-Crick Double Helix. Current 
Science 2003, 85 (11), 1556-1563. 
18. Liu, Y.; Chai, Y.; Kumar, A.; Boykin, D.; Wilson, W., Designed Compounds for 
Recognition of 10 Base Pairs of DNA with Two AT Binding Sites. Journal of the 
American Chemical Society 2012, 134 (11), 5290-9. 
 
APPENDIX 
The change in thermal melting temperature was used as a screening method for 
binding affinity. Typically, a ratio of 2:1 was used for comparison. In order to speed up 
data collection, several compounds were often tested at a single ratio with DNA. For 
each experiment, a graph of normalized absorbance vs. temperature was created. A 
combination of the derivative function and estimation from the graphs was used to 
determine the ΔTm values listed in Table 1. Initial DNA absorbance was typically 0.6-
0.8, and final DNA absorbance was typically 0.8-1.0. Hyperchromicity was 
approximately 24%. 
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Tm of DB224, DB322, DB334, DB1255, and A
3
CT
3
DNA
DB224 (2:1)
DB322 (2:1)
DB334 (2:1)
DB1255 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB232 and A
3
CT
3
DNA
1:1
2:1
3:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
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0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB321 and A
3
CT
3
DNA
1:1
2:1
3:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB323, DB1998, and A
3
CT
3
DNA
DB323 (2:1)
DB1998 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
 
0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB325, DB496, DB2247, DB2260, and A
3
CT
3
DNA
DB325 (2:1)
DB496 (2:1)
DB2247 (2:1)
DB2260 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB462 and A
3
CT
3
DNA
1:1
2:1
3:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
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0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB510 and A
3
CT
3
DNA
1:1
2:1
3:1
N
o
rm
a
li
z
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB1791 and A
3
CT
3
DNA
1:1
2:1
3:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
 
0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB1947 and A
3
CT
3
DNA
1.5:1
3:1
4:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB2119, DB2120, DB2239, DB2240, and A
3
CT
3
DNA
DB2119 (2:1)
DB2120 (2:1)
DB2239 (2:1)
DB2240 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
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0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB2148 and A
3
CT
3
 
DNA
1:1
2:1
3:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB2149 and A
3
CT
3
DNA
1:1
2:1
3:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
 
0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB2150 and A
3
CT
3
DNA
1:1
2:1
3:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB2120, DB2246, DB2265, and A
3
CT
3
DNA
DB2120 (2:1)
DB2246 (2:1)
DB2265 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
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0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB2246, DB2265, and A
3
CT
3
DNA
DB2246 (2:1)
DB2265 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB2232, DB2237, DB2238, and A
3
CT
3
DNA
DB2232 (2:1)
DB2237 (2:1)
DB2238 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
 
 
A3T3: 
0
0.2
0.4
0.6
0.8
1
50 60 70 80 90
Tm of A
3
T
3,
 DB224, DB323, DB334, and DB2204
DNA
DB224 (2:1)
DB323 (2:1)
DB334 (2:1)
DB2204 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)           
0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB232 and A
3
T
3
DNA
1:1
2:1
3:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
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0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB321 and A
3
T
3
DNA
1:1
2:1
3:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB322 and A
3
T
3
DNA
1:1
2:1
3:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
 
0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB323, DB334, and A
3
T
3
DNA
DB323 (2:1)
DB334 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB325, DB496, DB2247, DB2260, and A
3
T
3
 
DNA
DB325 (2:1)
DB496 (2:1)
DB2247 (2:1)
DB2260 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
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0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB462 and A
3
T
3
 
DNA
1:1
2:1
3:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB510 and A
3
T
3 
HP
DNA
1:1
2:1
3:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
 
0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB1255, DB1998, and A
3
T
3
 
DNA
DB1255 (2:1)
DB1998 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB1791 and A
3
T
3
DNA
1:1
2:1
3:1N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
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0
0.2
0.4
0.6
0.8
1
50 60 70 80 90
Tm of DB1947, DB2148, DB2149, DB2150, and A
3
T
3
DNA
DB1947 (3:1)
DB2148 (2:1)
DB2149 (2:1)
DB2150 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB2119, DB2120, DB2239, DB2240, and A
3
T
3
DNA
DB2119 (2:1)
DB2120 (2:1)
DB2239 (2:1)
DB2240 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
 
0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB2232, DB2237, DB2238, and A
3
T
3
DNA
DB2232 (2:1)
DB2237 (2:1)
DB2238 (2:1)
N
o
rm
a
z
lie
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
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A4GCT4: 
0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of A
4
GCT
4
, DB224, DB322, and DB2224
DNA
DB224 (2:1)
DB322 (2:1)
DB2224 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB232 and A
4
GCT
4
DNA
1:1
2:1
3:1
N
o
rm
a
li
z
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
 
0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB321 and A
4
GCT
4
DNA
1:1
2:1
4:1
6:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of A
4
GCT
4
, DB322, DB323, and DB334
DNA
DB322 (2:1)
DB323 (2:1)
DB334 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
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0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB323, DB1255, DB1998, DB2204, and A
4
GCT
4
DNA
DB323 (2:1)
DB1255 (2:1)
DB1998 (2:1)
DB2204 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB462 and A
4
GCT
4
DNA
1:1
2:1
3:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
 
0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB510 and A
4
GCT
4
DNA
1:1
2:1
3:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB1746 and A
4
GCT
4
DNA
1:1
2:1
3:1
N
o
rm
a
li
z
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
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0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB1747 and A
4
GCT
4
DNA
1:1
2:1
3:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of 1C, 3C, and 5C-Linker Cyanines, DB1791, and A
4
GCT
4
DNA
1C-Linker Cyanine (2:1)
3C -Linker Cyanine (2:1)
5C-Linker Cyanine (2:1)
DB1791 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
 
0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB2119, DB2120, DB2239, DB2240, and A
4
GCT
4
DNA
DB2119 (2:1)
DB2120 (2:1)
DB2239 (2:1)
DB2240 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB2147 and A
4
GCT
4
 
DNA
1:1
2:1
3:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
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0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB2148 and A
4
GCT
4
DNA
1:1
2:1
3:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
40 50 60 70 80
Tm of DB2149, DB2150, and A
4
GCT
4
DNA
DB2149 1:1
DB2149 2:1
DB2150 1:1
DB2150 2:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
 
0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB2201 and A
4
GCT
4
DNA
1:1
2:1
3:1N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB2232, DB2237, DB2238, and A
4
GCT
4
DNA
DB2232 (2:1)
DB2237 (2:1)
DB2238 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
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(AAG)3: 
0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB224, DB322, DB323, DB334, and (AAG)
3
DNA
DB224 (2:1)
DB322 (2:1)
DB323 (2:1)
DB334 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB224, DB323, DB334, DB510, and (AAG)
3
DNA
DB224 (2:1)
DB323 (2:1)
DB334 (2:1)
DB510 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
 
0
0.2
0.4
0.6
0.8
1
50 60 70 80 90
Tm of DB322 and (AAG)
3
DNA
1:1
2:1
3:1
N
o
rm
a
z
lie
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB325, DB496, DB2247, DB2260, and (AAG)
3
DNA
DB325 (2:1)
DB496 (2:1)
DB2247 (2:1)
DB2260 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
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0
0.2
0.4
0.6
0.8
1
50 60 70 80 90
Tm of DB1255, DB1998, DB2204, and (AAG)
3
DNA
DB1255 (2:1)
DB1998 (2:1)
DB2204 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
60 65 70 75 80 85 90 95
Tm of DB1791, DB2201, and (AAG)
3
DNA
DB1791 (2:1)
DB2201 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
 
0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB2119, DB2120, DB2239, DB2240, and (AAG)
3
DNA
DB2119 (2:1)
DB2120 (2:1)
DB2239 (2:1)
DB2240 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
60 65 70 75 80 85 90 95
Tm of DB2147, DB2148, DB2149, DB2150, and (AAG)
3
DNA
DB2147 (2:1)
DB2148 (2:1)
DB2149 (2:1)
DB2150 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
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0
0.2
0.4
0.6
0.8
1
50 60 70 80 90
Tm of DB2246, DB2265, and (AAG)
3
DNA
DB2246 (2:1)
DB2265 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
50 60 70 80 90
Tm of (AAG)
3
, DB2232, DB2237, and DB2238 
DNA
DB2232 (2:1)
DB2237 (2:1)
DB2238 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
 
 
(AT)4: 
0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB224, DB323, DB334, DB510, and (AT)
4
 
DNA
DB224 (2:1)
DB323 (2:1)
DB334 (2:1)
DB510 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB232 and (AT)
4
DNA
1:1
2:1
3:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
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0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB321 and (AT)
4
DNA
1:1
2:1
4:1
6:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
50 60 70 80 90
Tm of DB322 and (AT)
4
DNA
1:1
2:1
3:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
 
0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB325, DB496, DB2247, DB2260, and (AT)
4
DNA
DB325 (2:1)
DB496 (2:1)
DB2247 (2:1)
DB2260 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB462 and (AT)
4
DNA
1:1
2:1
3:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
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0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB510 and (AT)
4
DNA
1:1
2:1
3:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB1255, DB1998, DB2204, DB2224, and (AT)
4
DNA
DB1255 (2:1)
DB1998 (2:1)
DB2204 (2:1)
DB2224 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
 
0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB1791 and (AT)
4
DNA
1:1
2:1
3:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB2119, DB2120, DB2239, DB2240, and (AT)
4
DNA
DB2119 (2:1)
DB2120 (2:1)
DB2239 (2:1)
DB2240 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
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0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB510 and (AT)
4
DNA
1:1
2:1
3:1
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB1255, DB1998, DB2204, DB2224, and (AT)
4
DNA
DB1255 (2:1)
DB1998 (2:1)
DB2204 (2:1)
DB2224 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
 
0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB2232, DB2237, DB2238, and (AT)
4
DNA
DB2232 (2:1)
DB2237 (2:1)
DB2238 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
30 40 50 60 70 80 90
Tm of DB2246, DB2247, and (AT)
4
DNA
DB2246 (2:1)
DB2247 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)  
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A4: 
0
0.2
0.4
0.6
0.8
1
40 50 60 70 80 90
Tm of DB224, DB323, DB1255, DB1998, and A
4
DNA
DB224 (2:1)
DB323 (2:1)
DB1255 (2:1)
DB1998 (2:1)
N
o
rm
a
liz
e
d
 A
b
s
o
rb
a
n
c
e
Temperature (°C)          
0
0.2
0.4
0.6
0.8
1
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